Page last updated: 2024-11-07

saframycin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

saframycin A: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100594
CHEMBL ID452709
SCHEMBL ID637953
MeSH IDM0087968

Synonyms (4)

Synonym
saframycin a
CHEMBL452709
SCHEMBL637953
n-[[(1r,2s,10r,12r,13s)-12-cyano-7,18-dimethoxy-6,17,21-trimethyl-5,8,16,19-tetraoxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraen-10-yl]methyl]-2-oxopropanamide

Research Excerpts

Overview

Saframycin A (SFM-A) is a potent antitumor antibiotic that belongs to the tetrahydroisoquinoline family. It is a member of a class of natural products with potent antiproliferative effects.

ExcerptReferenceRelevance
"Saframycin A is a potent antitumor antibiotic with a unique pentacyclic tetrahydroisoquinoline scaffold. "( Reconstruction of the saframycin core scaffold defines dual Pictet-Spengler mechanisms.
Koketsu, K; Oguri, H; Oikawa, H; Suda, H; Watanabe, K, 2010
)
1.8
"Saframycin A (SFM-A) is a potent antitumor antibiotic that belongs to the tetrahydroisoquinoline family. "( Characterization of SfmD as a Heme peroxidase that catalyzes the regioselective hydroxylation of 3-methyltyrosine to 3-hydroxy-5-methyltyrosine in saframycin A biosynthesis.
Fu, CY; Tang, GL; Tang, MC, 2012
)
2.02
"Saframycin A (SafA) is a member of a class of natural products with potent antiproliferative effects in leukemia- and tumor-derived cells. "( Identification of GAPDH as a protein target of the saframycin antiproliferative agents.
Barbay, JK; LaPorte, JR; Myers, AG; Xing, C, 2004
)
2.02
"Saframycin A (SafA) is a natural product that inhibits human cancer cell proliferation. "( Transcriptional response pathways in a yeast strain sensitive to saframycin a and a more potent analog: evidence for a common basis of activity.
Myers, AG; Plowright, AT; Schaus, SE, 2002
)
2
"Saframycin A is an antitumor antibiotic produced by Streptomyces lavendulae 314 which falls into the category of the N-heterocyclic quinone group. "( Directed biosynthesis of new saframycin derivatives with resting cells of Streptomyces lavendulae.
Arai, T; Maeda, A; Mikami, Y; Takahashi, K; Yazawa, K, 1985
)
1.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
saframycin A biosynthesis618

Bioassays (14)

Assay IDTitleYearJournalArticle
AID356602Cytotoxicity against human NCI-H460 cells after 4 days2003Journal of natural products, Nov, Volume: 66, Issue:11
Chemistry of renieramycins. Part 3.(1) isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide.
AID644360Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID644357Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID644358Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID644354Cytotoxicity against human Bel7402 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID356600Cytotoxicity against human HCT116 cells after 4 days2003Journal of natural products, Nov, Volume: 66, Issue:11
Chemistry of renieramycins. Part 3.(1) isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide.
AID644353Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID644361Cytotoxicity against human HELF cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID644359Cytotoxicity against human BGC803 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID356601Cytotoxicity against human QG56 cells after 4 days2003Journal of natural products, Nov, Volume: 66, Issue:11
Chemistry of renieramycins. Part 3.(1) isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide.
AID644362Cytotoxicity against human KB cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID356603Cytotoxicity against human DLD1 cells after 4 days2003Journal of natural products, Nov, Volume: 66, Issue:11
Chemistry of renieramycins. Part 3.(1) isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide.
AID644356Cytotoxicity against human A2780 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
AID644355Cytotoxicity against human Ketr3 cells assessed as cell viability after 72 hrs by MTT assay2012European journal of medicinal chemistry, Mar, Volume: 49Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (42.11)18.7374
1990's4 (10.53)18.2507
2000's8 (21.05)29.6817
2010's7 (18.42)24.3611
2020's3 (7.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.48 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]